Eam Investors, LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Eam Investors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$61.35 - $90.47 $1.94 Million - $2.87 Million	-31,690 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$43.82 - $85.37 $1.39 Million - $2.71 Million	31,690 New	31,690 $2.43 Million
Q1 2020 May 13, 2020	SELL	$20.56 - $63.12 $1.04 Million - $3.18 Million	-50,411 Closed	0 $0
Q4 2019 Feb 11, 2020	SELL	$28.14 - $73.01 $1.27 Million - $3.29 Million	-45,097 Reduced 47.22%	50,411 $3.2 Million
Q3 2019 Nov 13, 2019	BUY	$26.26 - $34.86 $600,618 - $797,317	22,872 Added 31.49%	95,508 $2.69 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $139,562 - $230,761	-8,007 Reduced 9.93%	72,636 $1.93 Million
Q1 2019 May 13, 2019	SELL	$12.05 - $20.18 $72,938 - $122,149	-6,053 Reduced 6.98%	80,643 $1.48 Million
Q4 2018 Feb 13, 2019	SELL	$10.74 - $19.7 $1.73 Million - $3.17 Million	-160,853 Reduced 64.98%	86,696 $1.08 Million
Q3 2018 Nov 08, 2018	BUY	$14.0 - $20.3 $2.28 Million - $3.31 Million	162,916 Added 192.5%	247,549 $4.75 Million
Q2 2018 Aug 03, 2018	BUY	$6.37 - $14.02 $539,112 - $1.19 Million	84,633 New	84,633 $1.15 Million

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.